Over the past several months, the United States has rapidly accelerated its COVID-19 vaccination rates, with close to half of the population receiving at least one dose by the middle of May. With three highly effective vaccine options and numerous public-private partnerships delivering doses to the public, the country certainly appears to be on the right track to building immunity to the virus. However, a closer look at the data reveals significant concerns. There are clear and persistent
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
4G Clinical Secures $230M for Randomization and Trial Supply Management
What You Should Know:
- 4G Clinical, a cutting-edge randomization and trial supply management (RTSM) company, today announced it has entered into an agreement to receive a growth equity investment of over $230MM from Goldman Sachs Asset Management ("Goldman Sachs").
- Founded in 2015, 4G Clinical's Prancer RTSMⓇ enables life sciences companies to reach First Patient In (FPI) up to 50% faster than other providers and implement mid-study changes more efficiently. 4G Clinical's clinical
Read More
Hospitals Can Teach Life Science Companies a Thing or Two About Patient Engagement
The efforts to develop a COVID-19 vaccine focused the world’s attention on the pharmaceutical industry. Before the pandemic hit, very few people outside of the healthcare industry understood what it takes to develop a new drug. Nor did they consider the complexities of administering the various medications that require a regimen that goes beyond “take one pill each morning.”
The biopharmaceutical industry is massive, accounting for more than $1.3 trillion in economic output, representing four
Read More
Medable Launches Decentralized Clinical Trials Enablement Program
What You Should Know:
- Medable Inc., a software platform for patient-centered drug development, today announced an industry-first digital certification program that provides life sciences companies with specialized tools, knowledge sharing and skills development to rapidly scale their decentralized and hybrid trial strategies.
- Hybrid/decentralized clinical trials have unleashed an entirely new patient experience, but this new approach to clinical research will only work if
Read More
RapidPulse Launches with $15M for Ischemic Stroke Therapy
- RapidPulse, Inc., a Miami-based medical device company developing a novel aspiration system to treat ischemic stroke, today announced it has raised $15M in Series A funding led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.
- The RapidPulse system was developed by Syntheon, a medical device incubator focused on developing next-generation medical devices, and has commercialized some of the largest and most trusted
Read More
Lightship Partners with Castor to Scale Virtual Clinical Trials Worldwide
- Lightship and Castor, providers of decentralized clinical trial solutions, today announced a strategic partnership to run direct-to-patient (hybrid) clinical trials at scale. The partnership combines operational excellence in clinical studies and technology that delivers for the most complex clinical trials.
- Lightship’s end-to-end delivery model combined with an in-house care team provide the best possible patient experience in clinical trials.
- By partnering with Castor’s
Read More
Benchling Launches New RNA Capabilities to Accelerate Drug Discovery
What You Should Know:
- Benchling, the leading life sciences cloud, today announced the launch of RNA Therapeutics R&D, a new digital solution that allows scientists to design, analyze, and develop complex RNA therapeutics in a unified cloud platform for the first time.
- More than 1,000 R&D organizations/customers can now accelerate collaboration, speed, and simplicity for RNA research via Benchling — an important advance for biotech.
Biopharmaceutical R&D teams can
Read More
Medidata Announces Decentralized Clinical Trials Program
What You Should Know:
- Today Medidata, a Dassault Systèmes company, announced the launch of the Medidata Decentralized Clinical Trials (DCT) Program, the most comprehensive set of unified, secure technologies that enable full decentralization across the clinical trial continuum.
For the first time ever, drug, vaccine, and medical device developers (sponsors) and contract research organizations (CROs) can take advantage of the only platform offering on the market which combines:
-
Read More
Hawthorne Effect Secures $20M to Decentralize Clinical Trials
What You Should Know:
- Hawthorne Effect, a San Francisco-based solution for decentralizing clinical trials, today announced it has raised $20M in Series A funding led by Northpond Ventures with participation from SignalFire and P5 Health Ventures.
- Founded in 2015, Hawthrone Effect alleviates key issues related to patient recruitment and retention via its tech-driven platform and expansive network of medical professionals.
Hawthrone’s key offerings include:
- Hawthorne Cloud: The
Read More
Medidata Launches New Tech to Transform the Patient Clinical Trial Experience
What You Should Know:
- Today Medidata, a Dassault Systèmes company, launched myMedidata Registries – a new technology that expands and strengthens the company’s myMedidata patient portal to engage patients before and after (i.e., long term follow-up/safety surveillance) a clinical trial.
- The offering, which redefines Medidata’s end-to-end technology solutions and represents a major advance for the life sciences industry, empowers patients to
Read More
